Drug Trial Radar · NCT04423393
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
May 26, 2020
Primary completion
Oct 24, 2022
Study completion Nov 25, 2022
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only in participants with chronic HBV infection).
Conditions
- Chronic Hepatitis B
Interventions
VIR-3434Biological
VIR-3434 given by subcutaneous injection or intravenous infusion.
PlaceboOther
Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D
- Number of Participants With Clinical Laboratory AbnormalitiesTime frame: Up to 280 days post-dose
Locations
24 sites in 7 countries. Site status is shown where the registry gives one.
Investigative Site
Essen, Germany
Investigative Site
Frankfurt, Germany
Investigative Site
Hanover, Germany
Investigative Site
Leipzig, Germany
Investigative Site
Mainz, Germany
Investigative Site
Mannheim, Germany
Investigative Site
Ulm, Germany
Investigative Site
Hong Kong, Hong Kong
Investigative Site
Auckland, New Zealand
Investigative Site
Havelock North, New Zealand
Investigative Site
Newtown, New Zealand
Investigative Site
Tauranga, New Zealand
Investigative Site
Bucharest, Romania
Investigative Site
Singapore, Singapore
Investigative Site
Singapore, Singapore
Investigative Site
Busan, South Korea
Investigative Site
Busan, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Birmingham, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.